Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 45Breast Neoplasms 39Triple Negative Breast Neoplasms 19Prostatic Neoplasms 17Neoplasms 13Fallopian Tube Neoplasms 13Endometrial Neoplasms 12Recurrence 8Pancreatic Neoplasms 8Neoplasm Metastasis 8Squamous Cell Carcinoma of Head and Neck 7Small Cell Lung Carcinoma 7Lung Neoplasms 6Carcinoma, Ovarian Epithelial 6Glioma 5Glioblastoma 5Carcinoma, Renal Cell 5Uterine Cervical Neoplasms 4Sarcoma 4Carcinoma, Squamous Cell 4Carcinoma, Non-Small-Cell Lung 4Advanced Breast Cancer 4Stomach Neoplasms 3Solid Tumor 3Melanoma 3Head and Neck Neoplasms 3Fanconi Anemia, Complementation Group D1 3Uveal Melanoma 2Uterine Neoplasms 2Urinary Bladder Neoplasms 2

Interventions

Gemcitabine 5Irinotecan 2Albumin-Bound Paclitaxel 2regorafenib 1pembrolizumab 1olaparib 1ibrutinib 1Tetrahydrouridine 1Telemedicine 1Taxes 1Practice Guidelines as Topic 1Paclitaxel 1Oxaliplatin 1Leucovorin 1Fluorouracil 1Erlotinib Hydrochloride 1Docetaxel 1Decitabine 1Counseling 1Cisplatin 1Capecitabine 1BKT140 14-fluorobenzoyl-TN-14003 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Pancreatic Adenocarcinoma × olaparib × Clear all
NCT02677038 2024-10-01

Olaparib in Treating Patients With Stage IV Pancreatic Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
24 enrolled 8 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡